Will VistaGen Therapeutics Inc. (VTGN) Future Potential Be Hindered By Price Volatility?
VistaGen Therapeutics Inc. (NASDAQ:VTGN) has a beta value of 0.87 and has seen 1.39 million shares traded in the last trading session. The company, currently valued at $400.95M, closed the last trade at $2.79 per share which meant it lost -$0.01 on the day or -0.36% during that session. The VTGN stock price is -13.98% off its 52-week high price of $3.18 and 83.51% above the 52-week low of $0.46. If we look at the companys 10-day average daily trading volume, we find that it stood at 1.69 million shares traded. The 3-month trading volume is 2.19 million shares. The consensus among analysts is that VistaGen Therapeutics Inc. (VTGN) is a Buy stock at the moment, with a recommendation rating of 1.40. 0 analysts rate the stock as a Sell, while 1 rate it as Overweight. 0 out of 4 have rated it as a Hold, with 3 advising it as a Buy. 0 have rated the stock as Underweight. The expected earnings per share for the stock is -$0.05. VistaGen Therapeutics Inc. (NASDAQ:VTGN) trade information  Sporting -0.36% in the red in last session, the stock has traded in the green over the last five days, with the highest price hit on Monday, 06/14/21 when the VTGN stock price touched $2.79 or saw a rise of 3.46%. Year-to-date, VistaGen Therapeutics Inc. shares have moved 43.81%, while the 5-day performance has seen it change 7.72%. Over the past 30 days, the shares of VistaGen Therapeutics Inc. (NASDAQ:VTGN) have changed 30.99%. Short interest in the company has seen 6.74 million shares shorted with days to cover at 1.91. Wall Street analysts have a consensus price target for the stock at $7.25, which means that the shares value could jump 61.52% from current levels. The projected low price target is $5.00 while the price target rests at a high of $9.00. In that case, then, we find that the current price level is -222.58% off the targeted high while a plunge would see the stock gain -79.21% from current levels. VistaGen Therapeutics Inc. (VTGN) estimates and forecasts  Figures show that VistaGen Therapeutics Inc. shares have outperformed across the wider relevant industry. The companys shares have gained 271.01% over the past 6 months, with this year growth rate of 54.00%, compared to 8.70% for the industry. Other than that, the company has, however, increased its growth outlook for the 2021 fiscal year revenue. Growth estimates for the current quarter are 28.60% and 14.30% for the next quarter. 4 analysts offering their estimates for the company have set an average revenue estimate of $230k for the current quarter. 3 have an estimated revenue figure of $300k for the next quarter concluding in Jun 2021. If we evaluate the companys growth over the last 5-year and for the next 5-year period, we find that annual earnings growth was 45.60% over the past 5 years. 5 Stocks Under $10 That Are Poised to Take Off Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck. Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck. Add them to your watchlist before they take off! Get the Top 5 Stocks Now! Sponsored  VTGN Dividends  VistaGen Therapeutics Inc. is expected to release its next earnings report in July this year, and investors are excited at the prospect of better dividends despite the companys debt issue. VistaGen Therapeutics Inc. (NASDAQ:VTGN)s Major holders  Insiders own 0.23% of the company shares, while shares held by institutions stand at 81.60% with a share float percentage of 81.79%. Investors are also buoyed by the number of investors in a company, with VistaGen Therapeutics Inc. having a total of 78 institutions that hold shares in the company. The top two institutional holders are NEA Management Company, LLC with over 16.3 million shares worth more than $34.72 million. As of Mar 30, 2021, NEA Management Company, LLC held 11.37% of shares outstanding. The other major institutional holder is VR Adviser, LLC, with the holding of over 16.3 million shares as of Mar 30, 2021. The firms total holdings are worth over $34.72 million and represent 11.37% of shares outstanding. Also the top two Mutual Funds that are holding companys shares are Vanguard Total Stock Market Index Fund and Franklin Strategic Series-Franklin Biotechnology Discove. As of Mar 30, 2021, the former fund manager holds about 2.58% shares in the company for having 3.7 million shares of worth $7.87 million while later fund manager owns 2.61 million shares of worth $5.53 million as of Jan 30, 2021, which makes it owner of about 1.82% of companys outstanding stock.